Ibrutinib

Name: Ibrutinib
Availability: ibrutinib-357388.html

Category:Active Pharmaceutical Ingredients > Other Active Pharmaceutical Ingredients
Product Name:Ibrutinib
CAS No.:936563-96-1
Standard:In-house Standards
Price(USD):Negotiable
Company:Shenzhen Haorui Pharmatech Co., Ltd.

Send Inquiry

Favorites

Similar Products

Coenzyme Q10

carbomer 974P

Propantheline Bromide

Hydrocortisone

Black Currant Extract

Refined Fish Oil

Basic Info

Grade: Pharmaceutical Grade

Factory Location: Hubei

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no

Payment Terms: L/C

Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014.

Send your message to this supplier

From:
To:
Shenzhen Haorui Pharmatech Co., Ltd.
Send a Copy to this Email
Message:
Upload Images / Files
- Supports jpg, jpeg, png,
gif, pdf, doc, docx,
xls, xlsx, txt, rar and zip
- Max upload 3 files;
Max total size: 3MB
(0/3)

Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now
Verification:

Ibrutinib

You may like